Publication | Open Access

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Hematological MalignancyMedicineHematologyClinical TrialsPharmacologyCytarabine Versus PlaceboMyeloid NeoplasiaPharmacotherapyOncologyCancer ResearchHealth Sciences